We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Penumbra's expanding thrombectomy portfolio and strong adoption of CAVT tech are driving revenue growth.
PEN boosts global reach; 22.2% of 2025 revenues generated from international markets and growth across Europe.
FX volatility and rising SG&A costs tied to hiring may weigh on Penumbra's near-term profitability.
Penumbra, Inc.’s (PEN - Free Report) robust product portfolio expansion is poised to drive growth in the upcoming quarters. The company’s global expansion efforts are thriving. Unfavorable foreign exchange and a dull macroeconomic scenario may pose operational risks for PEN.
In the past year, shares of this Zacks Rank #3 (Buy) company have risen 24.8% against the industry’s 7.2% decline. The S&P 500 composite has risen 18.7%.
The global healthcare provider company has a market capitalization of $13.18 billion. PEN beat on earnings in each of the trailing four quarters, the average surprise being 11.3%.
Tailwinds for Penumbra
Strong Portfolio Expansion: Penumbra is advancing its proprietary thrombectomy technologies across the United States and internationally, with consistent revenue growth driven by strong adoption of its CAVT portfolio. Lightning Bolt 6X and Lightning Bolt 7 are accelerating physician conversions from surgery, analytics and other mechanical thrombectomy platforms in arterial cases.
The Element Vascular Access System, launched in 2025, complements Flash 2.0 in VTE treatment. Ruby XL also began shipping in 2025, expanding Penumbra’s peripheral embolization portfolio to cover approximately 20% of the market previously untapped.
RED 72 (SILVER LABEL) has seen strong physician uptake in 2025, while RED 43 continues to lead in distal occlusions. The company announced results from the landmark STORM-PE randomized controlled trial (RCT), which showed that CAVT combined with anticoagulation achieved a superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-to-high-risk pulmonary embolism. Meanwhile, the STRIDE II trial has been launched to evaluate next-generation CAVT technology in arterial cases.
Global Expansion Continues: Penumbra derives a significant portion of its revenues internationally (22.2% in 2025). The company expects to materially increase both revenues and profitability in the company’s international business in the next few years.
Recently, Penumbra expanded its CAVT footprint into Europe and other markets outside the United States, while taking steps to optimize its global presence to support long-term growth and profitability. The company had previously launched the RED 72 SILVER LABEL catheter for stroke, along with its computer-orchestrated thrombectomy systems, Lightning 12 and Lightning 7, in Europe. With the continued rollout of these innovations, Penumbra expects a meaningful impact on international growth through 2025 and beyond.
What Ails PEN Stock?
Macroeconomic Concerns: Outside the United States, Penumbra sells its products to healthcare providers through direct sales organizations and distributors in select international markets. The wide presence makes its operations vulnerable to macroeconomic risks, including disruptions to global trade resulting from changes in trade agreements or tariffs.
Image Source: Zacks Investment Research
While the company has been able to offset much of the impact through favorable product mix and productivity improvements, selling, general and administrative (SG&A) expenses still rose 22.4% year over year in the fourth quarter of 2025, largely due to targeted hiring in the company’s commercial and market access teams. These investments, alongside ongoing macroeconomic challenges, are expected to weigh on near-term profitability.
Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. In 2025, approximately 22% of the company's consolidated revenues came from the non-U.S. markets. PEN’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2026 earnings has remained unchanged at $5.06 per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.59 billion, indicating a 12.9% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical has an earnings yield of 5.2%, well ahead of the industry’s -1.6% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 15.9% against the industry’s 7.5% decline over the past year.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% return. Shares of the company have soared 156.6% against the industry’s 20.5% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 2.1% against the industry’s 0.7% decline. Shares of the company have dropped 6.2% compared with the industry’s 7.4% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Key Takeaways
Penumbra, Inc.’s (PEN - Free Report) robust product portfolio expansion is poised to drive growth in the upcoming quarters. The company’s global expansion efforts are thriving. Unfavorable foreign exchange and a dull macroeconomic scenario may pose operational risks for PEN.
In the past year, shares of this Zacks Rank #3 (Buy) company have risen 24.8% against the industry’s 7.2% decline. The S&P 500 composite has risen 18.7%.
The global healthcare provider company has a market capitalization of $13.18 billion. PEN beat on earnings in each of the trailing four quarters, the average surprise being 11.3%.
Tailwinds for Penumbra
Strong Portfolio Expansion: Penumbra is advancing its proprietary thrombectomy technologies across the United States and internationally, with consistent revenue growth driven by strong adoption of its CAVT portfolio. Lightning Bolt 6X and Lightning Bolt 7 are accelerating physician conversions from surgery, analytics and other mechanical thrombectomy platforms in arterial cases.
The Element Vascular Access System, launched in 2025, complements Flash 2.0 in VTE treatment. Ruby XL also began shipping in 2025, expanding Penumbra’s peripheral embolization portfolio to cover approximately 20% of the market previously untapped.
RED 72 (SILVER LABEL) has seen strong physician uptake in 2025, while RED 43 continues to lead in distal occlusions. The company announced results from the landmark STORM-PE randomized controlled trial (RCT), which showed that CAVT combined with anticoagulation achieved a superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-to-high-risk pulmonary embolism. Meanwhile, the STRIDE II trial has been launched to evaluate next-generation CAVT technology in arterial cases.
Global Expansion Continues: Penumbra derives a significant portion of its revenues internationally (22.2% in 2025). The company expects to materially increase both revenues and profitability in the company’s international business in the next few years.
Recently, Penumbra expanded its CAVT footprint into Europe and other markets outside the United States, while taking steps to optimize its global presence to support long-term growth and profitability. The company had previously launched the RED 72 SILVER LABEL catheter for stroke, along with its computer-orchestrated thrombectomy systems, Lightning 12 and Lightning 7, in Europe. With the continued rollout of these innovations, Penumbra expects a meaningful impact on international growth through 2025 and beyond.
What Ails PEN Stock?
Macroeconomic Concerns: Outside the United States, Penumbra sells its products to healthcare providers through direct sales organizations and distributors in select international markets. The wide presence makes its operations vulnerable to macroeconomic risks, including disruptions to global trade resulting from changes in trade agreements or tariffs.
Image Source: Zacks Investment Research
While the company has been able to offset much of the impact through favorable product mix and productivity improvements, selling, general and administrative (SG&A) expenses still rose 22.4% year over year in the fourth quarter of 2025, largely due to targeted hiring in the company’s commercial and market access teams. These investments, alongside ongoing macroeconomic challenges, are expected to weigh on near-term profitability.
Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. In 2025, approximately 22% of the company's consolidated revenues came from the non-U.S. markets. PEN’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2026 earnings has remained unchanged at $5.06 per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.59 billion, indicating a 12.9% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical has an earnings yield of 5.2%, well ahead of the industry’s -1.6% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 15.9% against the industry’s 7.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% return. Shares of the company have soared 156.6% against the industry’s 20.5% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 2.1% against the industry’s 0.7% decline. Shares of the company have dropped 6.2% compared with the industry’s 7.4% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.